The mixed human umbilical cord bloodderived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro

Neurological Research

Volumn 33, Issue 4, 2011, Pages 405-414

  Jiao, Hongliang ^a,c   Yang, Bo ^a   Guan, Fangxia ^b   Li, Jianbin ^c   Shan, Hong ^c   Song, Laijun ^a   Hu, Xiang ^d   Liang, Shuo ^b   Du, Ying ^b   Jiang, Chao ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c Henan Province Red Cross Blood Center   (China)

^d Shenzhen Beike Cell Engineering Research Institute   (China)

Author keywords

C6 cells; Mesenchymal stem cells; Umbilical cord blood

Indexed keywords

CASPASE 3; CD133 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CELL THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG RESISTANCE; EFFECTOR CELL; ENZYME ACTIVITY; GLIOMA; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MESENCHYMAL STEM CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; TUMOR GROWTH; TUMOR IMMUNITY; UMBILICAL CORD BLOOD; UMBILICAL CORD BLOOD DERIVED MESENCHYMAL STEM CELL;

ANIMALS; ANTIGENS, CD; BRAIN NEOPLASMS; CASPASE 3; CELL COMMUNICATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FETAL BLOOD; GLIOMA; GLYCOPROTEINS; HUMANS; IMMUNOTHERAPY; INFANT, NEWBORN; INTERFERON-GAMMA; INTERLEUKIN-2; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; PEPTIDES; RATS;

EID: 79955964128     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164110X12816242542490     Document Type: Article

References (51)

1. Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, et al. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori 2007;93:248-56.
2. Kang SG, Kim JH, Nam DH, Park K. Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol Med Chir 2005;45:232-8.
3. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 2005;352:987-96.
4. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neuro-oncol 2007;83:53-60.
5. Kang SG, Kim JS, Park K, Kim JS, Groves MD, Nam DH. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 2006;15:7-13.
6. Scheda A, Finjap JK, Tuettenberg J, Brockmann MA, Hochhaus A, Hofheinz R, et al. Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Tumori 2007;93:31-6.
7. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang YF, Peng B, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006;12:4899-907.
8. Brower V. Search and destroy: recent research exploits adult stem cells' attraction to cancer. J Natl Cancer Inst 2005;97:414-6.
9. Barry FP. Biology and clinical applications of mesenchymal stem cells. Birth Defects Res C Embryo Today 2003;69:250-6.
10. Short B, Brouard N, Occhiodoro-Scott T, Ramakrishnan A, Simmons PJ. Mesenchymal stem cells. Arch Med Res 2003;34:565-71.
11. Kang SG, Ryu CH, Jeun SS, Park CK, Shin HJ, Kim JH, et al. Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood. Childs Nerv Syst 2004;20:154-62.
12. Kang SG, Jeun SS, Lim JY, Kim SM, Yang YS, Oh WI, et al. Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells. Childs Nerv Syst 2008;24:293-302.
13. Ray SK, Patel SJ, Welsh CT, Wilford GG, Hogan EL, Banik NL. Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. J Neurosci Res 2002;69:197-206.
14. Shinoura N, Muramatsu Y, Yoshida Y, Asai A, Kirino T, Hamada H. Adenovirus-mediated transfer of caspase-3 with Fas ligand induces drastic apoptosis in U-373MG glioma cells. Exp Cell Res 2000;256:423-33.
15. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
16. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133zcancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
17. Rosenberg SA, Lotze MT, Mule JJ. New approaches to the immunotherapy of cancer. Ann Intern Med 1988;108:853-64.
18. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenburg SA. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histologic findings. J Am Med Assoc 1986;256:3117-24.
19. Pizza G, Viza D, De Vinci C, Paschuchi JM, Busutti L, Bergami T. Intralymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study. Cytokine Res 1988;7:45-8.
20. Sama G, Collins J, Figlin R, Robertson P, Altrock B, Abels R. A pilot study of intralymphatic interleukin-2: II. Clinical and biological effects. J Biol Response Modif 1990;9:81-6.
21. Gandolfi L, Solmi L, Pizza GC, Bertoni F, Muratori R, De Vinci C, et al. Intratumoral echo-guided injection of interleukin-2 and lymphokine-activated killer cells in hepatocellular carcinoma. Hepatogastroenterology 1989;36:352-6.
22. Grivnik K, Anderson J. The role of T cell growth stimulating factors in T cell triggering. Immunol Rev 1980;51:35-59.
23. Ralph P, Nakoinz I, Rennick D. Role of interleukin 2, interleukin 4, and alpha, beta and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity. J Exp Med 1988;167:712-7.
24. Maraskovsky E, Chen W-F, Shortman K. IL-2 and IFNgamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989;143:1210-4.
25. Wallach D, Fellous M, Revel M. Preferential effect of interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982;299:833-6.
26. Carrel S, Schmidt-Kessen A, Giuffre L. Recombinant interferon-gamma can induce the expression of HLA-DR and-DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur J Immunol 1985;15:118-23.
27. Gross N, Beck D, Favre S, Carrel S. In vitro antigenic modulation of human neuroblastoma cells induced by IFNgamma, retinoic acid and dibutyryl cyclic AMP. Int J Cancer 1987;39:521-9.
28. Maheshwari RK, Srikantan V, Bhartiya D, Kleinman HK, Grant DS. Differential effects of interferon gamma and alpha on in vitro model of angiogenesis. J Cell Physiol 1991;146:164-9.
29. Yang SE, Ha CW, Jung M, Jin HJ, Lee M, Song H, et al. Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy 2004;6:476-86.
30. Kang SG, Jeun SS, Lim JY, Yoo DS, Huh PW, Cho KS, et al. Cytotoxicity of rat marrow stromal cells against malignant glioma cells. Childs Nerv Syst 2005;21:528-38.
31. Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, Goldbrunner R, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 2007;83:241-7.
32. Miletic H, Fischer Y, Litwak S, Giroglou T, Waerzeggers Y, Winkeler A, et al. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 2007;15:1373-81.
33. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-18.
34. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155-64.
35. Schichor C, Birnbaum T, Etminan N, Schnell O, Grau S, Miebach S, et al. Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 2006;199:301-10.
36. Pisati F, Belicchi M, Acerbi F, Marchesi C, Giussani C, Gavina M, et al. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Cancer Res 2007;67:3054-63.
37. Solves P, Moraga R, Saucedo E, Perales A, Soler MA, Larrea L, et al. Comparison between two strategies for umbilical cord blood collection. Bone Marrow Transplant 2003;31:269-73.
38. Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, et al. Substrate specificities of caspase family proteases. J Biol Chem 1997;272:9677-82.
39. Stennicke HR, Renatus M, Meldal M, Salvesen GS. Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8. Biochem J 2000;350:563-8.
40. Stennicke HR, Ryan CA, Salvesen GS. Reprieval from execution: the molecular basis of caspase inhibition. Trends Biochem Sci 2002;27:94-101.
41. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22:8543-67.
42. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
43. Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 2007;14:44-55.
44. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193:1007-8.
45. Bhagwati SN. Treatment of glioma with intratumoral instillation of autologous lymphocytes. Childs Nerv Syst 1989;5:38-40.
46. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995;76:840-52.
47. Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol 2001;39:31-42.
48. Huang Y, Hayes RL, Wertheim S, Arbit E, Scheff R. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report. Crit Rev Oncol Hematol 2001;39:17-23.
49. Jacobs SK, Parham CW, Holcomb B, Ikejiri B, Kornblith PL, Grimm EA. Lymphokine activated killer (LAK) cell mediated killing of human glioma: effect of pretreating glioma with various membrane modifying agents. J Neurooncol 1987;5:5-10.
50. Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, et al. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro. Cancer 1989;64:1629-37.
51. Merchant RE, Ellison MD, Young HF. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J Neurooncol 1990;8:173-88.